This designation is meaningful as it signifies our continued commitment to making biosimilars more accessible. Both biosimilars and interchangeable biosimilars are highly similar and have no ...

Adrian Clarke has cast his expert eye over all 90 minutes and delved into the stats to find out the secrets behind our ...

Relive all the glory again from Lisbon as we were crowned European champions for the second time against Barcelona ...

EBC-129 is the first made-in-Singapore antibody-drug conjugate (ADC) to enter clinical development. It selectively targets a tumour-specific N-glycosylated epitope on both CEACAM5 and CEACAM6.

As part of a $93 million grant package, the Cancer Prevention and Research Institute of Texas, known for funding ...

Galmed Pharmaceuticals Ltd. ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for the treatment of liver, cardiometabolic diseases and GI oncological indications, today announced ...

Butterfly Network, Inc. (NYSE: BFLY) delivered strong Q1 results with $21.2 million in revenue, up 20% from the prior year, ...

Reports continued progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare disease - - New data from pilot ...

Cipla USA Inc. (Cipla USA) announced its continued collaboration with the American Lung Association for the 11th annual LUNG FORCE Walk, reaffirming its commitment to advancing respiratory health and ...

This is more than a walk—it’s a movement toward greater understanding, accessibility, and opportunity for every ...

AstraZeneca is advancing its global efforts to transform cancer care by presenting pivotal data from its oncology portfolio ...